| 1 |
35368946 | Clinical Efficacy of Yiqi Yangyin Decoction Combined with Docetaxel on Advanced Ovarian Cancer and the Effect on the Levels of Serum Markers VEGF, HE4, and CA125. | 2022 |
2 |
| 2 |
32192322 | Efficacy of hypofractionated radiotherapy combined with docetaxel in middle and advanced non-small cell lung cancer and its effects on serum MMP-9 and VEGF expressions. | 2021 Dec |
1 |
| 3 |
33579470 | Tumor microenvironment responsive VEGF-antibody functionalized pH sensitive liposomes of docetaxel for augmented breast cancer therapy. | 2021 Feb |
10 |
| 4 |
32179814 | Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process. | 2020 Mar 16 |
1 |
| 5 |
33099941 | Efficacy of nedaplatin combined with docetaxel in patients with nasopharyngeal carcinoma and its influence on ECRG4 and VEGF expressions. | 2020 Jul-Aug |
4 |
| 6 |
31497882 | Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. | 2019 Nov |
1 |
| 7 |
27840955 | miR-141 regulation of EIF4E expression affects docetaxel chemoresistance of non-small cell lung cancer. | 2017 Jan |
2 |
| 8 |
28615679 | Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1. | 2017 Jun 14 |
1 |
| 9 |
29291019 | Insulin-like growth factor-I induces chemoresistence to docetaxel by inhibiting miR-143 in human prostate cancer. | 2017 Dec 5 |
1 |
| 10 |
26194374 | Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer. | 2016 Apr |
1 |
| 11 |
27122375 | The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer. | 2016 Nov |
4 |
| 12 |
24061601 | Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel. | 2014 Jun |
2 |
| 13 |
25275022 | Differential expression of VEGF and IL-1alpha after photodynamic treatment in combination with doxorubicin or taxotere. | 2014 Oct |
3 |
| 14 |
22608542 | Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines. | 2013 Nov |
1 |
| 15 |
23645743 | Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro. | 2013 May |
1 |
| 16 |
23481572 | Low dose chemotherapeutic drugs without overt cytotoxic effects decrease the secretion of VEGF by cultured human tumor cells: a tentative relationship between drug type and tumor cell type response. | 2012-2013 |
1 |
| 17 |
20592666 | Docetaxel-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome-related complex in a patient with metastatic prostate cancer? | 2011 Sep |
1 |
| 18 |
20862750 | A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. | 2011 Feb 1 |
2 |
| 19 |
21290245 | Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model. | 2011 Oct |
1 |
| 20 |
21323568 | Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases. | 2011 Jul |
1 |
| 21 |
22040497 | Comparison of the effects of recombinant human endostatin and docetaxel on human umbilical vein endothelial cells in different growth states. | 2011 Sep |
3 |
| 22 |
20729074 | Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment. | 2010 Nov |
3 |
| 23 |
20736943 | Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients. | 2010 Sep 7 |
1 |
| 24 |
19417018 | A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. | 2009 May 15 |
1 |
| 25 |
19447868 | Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. | 2009 May 15 |
7 |
| 26 |
17498666 | Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. | 2007 Jul 15 |
1 |
| 27 |
16415178 | The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere). | 2006 Apr |
1 |
| 28 |
16912198 | Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation. | 2006 Aug 15 |
9 |
| 29 |
16951177 | Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. | 2006 Sep 1 |
1 |
| 30 |
12820439 | The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status? | 2003 Mar-Apr |
2 |
| 31 |
12967483 | Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo. | 2003 Sep |
2 |
| 32 |
12970892 | Inhibitory effects of docetaxel on expression of VEGF, bFGF and MMPs of LS174T cell. | 2003 Sep |
3 |
| 33 |
12473607 | Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. | 2002 Dec |
1 |
| 34 |
12479700 | Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. | 2002 Nov |
1 |
| 35 |
11309294 | The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. | 2001 Apr 15 |
6 |
| 36 |
11724283 | Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. | 2001 Jul-Aug |
2 |